COVID, SARS-CoV 2
Conditions
Keywords
covid-19, SARS-Cov-2
Brief summary
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive). This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19, by analyzing associations between treatments and outcomes. All data are collected in electronical records during routine practice.
Detailed description
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive). This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19. Risk factors which will be studied include: baseline characteristics such as medical history and drugs with corresponding administration protocols. Main outcomes include all-cause mortality, need for mechanical ventilation, for ICU transfer and all relevant biological syndromes. All data are collected in electronical records during routine practice and additional data may be collected retrospectively.
Interventions
None listed
Sponsors
Groupe Hospitalier Pitie-Salpetriere
Centre Hospitalier Intercommunal Robert Ballanger
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* hospitalized for Covid-19 * severe pneumonia defined as pulse O2 \< 96% despite \> 6L/min
Exclusion criteria
* lack of consent * palliative care patients * patients in ICU * patients transferred from ICU
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite of death and mechanical ventilation | At 14-days follow-up | Composite of death and mechanical ventilation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Need for mechanical ventilation | At 14-days follow-up | Need for mechanical ventilation |
| Death | At 14-days follow-up | All-cause mortality |
| Acute respiratory distress syndrome | At 14-days follow-up | As defined by Berlin criteria: P/F ratio below 200, with PEEP \> +5 cmH20, radiologic findings compatible with ARDS and not explained by heart failure, occurring within 7 days of an acute pulmonary or non-pulmonary aggression. |
| Acute kidney injury | At 14-days follow-up | As defined by AKIN |
| Composite of death and mechanical ventilation | Up to 60 days after inclusion | Composite of death and mechanical ventilation |
| 60-days mortality | Up to 60 days after inclusion | All cause mortality at 60 days follow-up whenever possible |
| 60-days mechanical ventilation | Up to 60 days after inclusion | If patient was mechanically ventilated within 60 days of inclusion |
| Cardiac arrhythmia and conduction disorder | At 14-days follow-up | Documented by EKG monitoring |
Countries
France
Contacts
Primary ContactHélène Gros, MD
Outcome results
None listed